– USA, NJ – Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced the appointments of Dr. Sue Mahony (Ph.D.), Marie-France Tschudin, and Tim Walbert to its Board of Directors effective immediately.
“We are thrilled to welcome these biopharma leaders to our Board, whose expertise in navigating the complexities of the healthcare landscape will be invaluable,” said Board Chair, John Greisch. “We look forward to benefitting from their insights in support of Catalent’s mission to develop, manufacture and supply products that help people live better and healthier lives.”
About Dr. Susan Mahony
Dr. Sue Mahony is a senior executive with over 30 years of experience in pharmaceutical and life sciences companies. She served in a variety of senior leadership positions at Eli Lilly and Company from 2000 to 2018, most recently as SVP and President of Lilly Oncology and a member of the executive committee of Eli Lilly. Before joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering-Plough, Amgen, and Bristol Myers Squibb.
She serves on the board of directors of Assembly Biosciences, Inc., Axsome Therapeutics, Inc., and Zymeworks, Inc., and she previously served on the board of directors of Horizon Therapeutics, plc, and Vifor Pharma.
Dr. Mahony received a BSc and a Ph.D. from Aston University and an MBA from London Business School.
About Marie-France Tschudin
Marie-France Tschudin is a global healthcare leader with 30 years of experience in the biotechnology and pharma industry. Until September 2023, Ms. Tschudin was President, of Innovative Medicines International and CCO of Novartis Pharma AG and a member of the Executive Committee. Before that, she held increasingly senior leadership positions, including President, of Novartis Pharmaceuticals. Before joining Novartis, Ms. Tschudin spent 10 years at Celgene International in a variety of leadership positions across Europe. Ms Tschudin started her career as a sales representative and then held several sales and marketing positions at Johnson & Johnson and Schering-Plough.
She is a Board Director for AXA Group and Mars, Inc.
Marie-France Tschudin graduated with a Master of Business Administration from IMD Business School in Switzerland, and a Bachelor of Science from Georgetown University.
About Tim Walbert
Tim Walbert served as the Chairman, President, and CEO of Horizon Therapeutics from 2008 to October 2023, when it was acquired by Amgen for $28.3 billion. Before joining Horizon, he held various executive leadership positions across biotech and pharma companies, including at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic Humira. Mr. Walbert serves on the boards of directors of Century Therapeutics and Sagimet Biosciences, both public biotech companies, and Cour Pharmaceuticals, Odyssey Therapeutic, and Latigo Therapeutics (chairman), each private clinical-stage biotech company.
Tim Walbert received a Bachelor of Arts in Business from Muhlenberg College in Allentown, PA, and now serves as a member of the College’s Board of Trustees.
About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually.
For more: https://www.catalent.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.